Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically- or cytologically-confirmed diagnosis of stage IIIB or IV Non-Small Cell Lung Cancer
Received only one prior treatment (not including radiation)
Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST) guidelines
Life expectancy of ≥ 4 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematologic, renal and hepatic function
You may not be if
Brain metastases requiring treatment
History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline
Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment
Prior epidermal growth factor receptor targeting agents with the exception of the small molecule EGFr tyrosine kinase inhibitors
Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment
Prior therapy with sirolimus, sirolimus analogs
Immunosuppressive agents within 28 days before enrollment
